METHODS AND COMPOUNDS FOR DIAGNOSING THREONYL-tRNA SYNTHETASE-ASSOCIATED DISEASES AND CONDITIONS
AssigneeUiversity of Vermont and State Agricultural College
InventorsChristopher Francklyn, Karen M. Lounsbury, Tamara Williams
Life of this patent
Estimating the term…
Abstract
The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.
Claims31
A method of diagnosing a subject as having, or at increased risk of developing, a disorder associated with increased threonyl-tRNA synthetase (TARS) activity, the method comprising
- (a) obtaining a biological sample from a subject;
- (b) measuring the amount of a TARS molecule in the biological sample;
- and
- (c) comparing the level of the TARS molecule in the biological sample to a normal control level of the TARS molecule, wherein a significant increase in the level of the TARS molecule in the subject biological sample compared to the normal control level is an indication that the subject has or is at increased risk of developing the disorder associated with increased TARS activity.
(canceled)
(canceled)
11-12. (canceled)
(canceled)
(canceled)
18-22. (canceled)
A method for determining a prognosis in a subject diagnosed with a disorder associated with increased threonyl-tRNA synthetase (TARS) activity, the method comprising:
- (a) obtaining a biological sample from the subject;
- (b) measuring a TARS molecule level in the subject's biological sample;
- (c) comparing the TARS molecule level of the subject's sample with a control level of the TARS molecule;
- and
- (d) correlating levels of the TARS molecule greater than the control level with an indication of unfavorable prognosis and levels of the TARS molecule at or below the control level with a favorable prognosis.
(canceled)
28-29. (canceled)
32-36. (canceled)
A method for determining the metastatic potential of a cancer, the method comprising
- (a) obtaining a biological sample from a subject having a cancer;
- (b) measuring a level of a threonyl-tRNA synthetase (TARS) molecule in the biological sample;
- and
- (c) comparing the level of the TARS molecule in the biological sample to a control level of the TARS molecule, wherein a significantly higher level of the TARS molecule in the sample compared to the control level of the TARS molecule indicates a higher metastatic potential for the cancer.
38-40. (canceled)
43-53. (canceled)
Dependencies are inferred from the claim text.